Literature DB >> 7766977

Contrast-enhanced MR imaging of intrahepatic cholangiocarcinoma: pathologic correlation study.

T Murakami1, H Nakamura, K Tsuda, T Ishida, K Tomoda, S Hori, M Monden, T Kanai, K Wakasa, M Sakurai.   

Abstract

The authors describe the enhanced magnetic resonance (MR) imaging appearance of intrahepatic cholangiocarcinoma. The MR images of eight patients with intrahepatic cholangiocarcinoma who underwent MR examination within 3 weeks before partial hepatectomy were retrospectively studied. The MR images, including a dynamic study, were compared directly with pathologic and histologic findings. The peripheral region of the medullary subtype of cholangiocarcinoma, with many tumor cells, showed greater enhancement relative to liver parenchyma in the early phase. The peripheral region of the scirrhous subtype, with fewer tumor cells showed less enhancement in the early phase. In one patient, the thin rim of the medullary tumor showed less enhancement in the late phase, and this rim corresponded to the peripheral region of the medullary tumor with many tumor cells. The central region of tumors with a large amount of fibrous tissue showed prolonged enhancement in the late and delayed phases. The thin rim of liver parenchyma around the tumor showed less enhancement in the early phase and greater enhancement in the late phase; this rim corresponded to congestive liver parenchyma with dilated sinusoids. Intrahepatic cholangiocarcinoma shows various enhancement patterns, which depend on both the histologic subtype and the degree and distribution of fibrosis within the tumor.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7766977     DOI: 10.1002/jmri.1880050210

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  9 in total

1.  Intrahepatic cholangiocarcinoma: expert consensus statement.

Authors:  Sharon M Weber; Dario Ribero; Eileen M O'Reilly; Norihiro Kokudo; Masaru Miyazaki; Timothy M Pawlik
Journal:  HPB (Oxford)       Date:  2015-08       Impact factor: 3.647

2.  Magnetic resonance imaging of the liver: New imaging strategies for evaluating focal liver lesions.

Authors:  Kenneth Coenegrachts
Journal:  World J Radiol       Date:  2009-12-31

Review 3.  [Clinical relevance of the new S3 guideline on hepatocellular carcinoma and biliary tract cancer for practitioners].

Authors:  Sabrina Voesch; M Bitzer; N Malek
Journal:  Radiologe       Date:  2022-02-11       Impact factor: 0.635

4.  Value of Intravoxel Incoherent Motion (IVIM) Imaging for Differentiation between Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma.

Authors:  Jinhua Wang; Zhongxian Yang; Min Luo; Cui Xu; Mu Du; Yubao Liu
Journal:  Contrast Media Mol Imaging       Date:  2022-05-10       Impact factor: 3.009

5.  A case of hepatic inflammatory pseudotumor protruding from the liver surface.

Authors:  Takashi Obana; Shuuji Yamasaki; Kazushi Nishio; Yasushi Kobayashi
Journal:  Clin J Gastroenterol       Date:  2015-09-28

6.  Magnetic Resonance Imaging of cholangiocarcinoma.

Authors:  Katrina A Vanderveen; Hero K Hussain
Journal:  Cancer Imaging       Date:  2004-04-06       Impact factor: 3.909

7.  Solid focal liver lesions: dynamic and late enhancement patterns with the dual phase contrast agent gadobenate dimeglumine.

Authors:  Luigi Grazioli; Maria Pia Bondioni; Niccolò Faccioli; Sebastiana Gambarini; Rita Tinti; Günther Schneider; Miles Kirchin
Journal:  J Gastrointest Cancer       Date:  2010-12

8.  Histogram analysis of dynamic contrast-enhanced magnetic resonance imaging in the differential diagnosis of parotid tumors.

Authors:  Shiyu Xiang; Jiliang Ren; Zhipeng Xia; Ying Yuan; Xiaofeng Tao
Journal:  BMC Med Imaging       Date:  2021-12-17       Impact factor: 1.930

9.  Evaluation of Angiogenesis and Pathological Classification of Extrahepatic Cholangiocarcinoma by Dynamic MR Imaging for E-Healthcare.

Authors:  Jinyun Tan; Xijun Sun; Shaoyu Wang; Baoqin Ma; Zhaohui Chen; Yaowei Shi; Li Zhang; Mohd Asif Shah
Journal:  J Healthc Eng       Date:  2021-10-11       Impact factor: 2.682

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.